Download full report with analyst certification and important disclosures
May 11 2020, 07:20 IST/BST
Amryt’s results this morning provide us with more clarity on how it is performing post the Aegerion acquisition (late Q3 2019). The numbers are impressive; strong revenue growth, positive EBITDA, a quarter ahead of schedule, and a robust cash balance. Minimal impact has been experienced, nor is much expected, from COVID-19. Looking forward, AP101 phase III trial results are due late Q3/early Q4, for which the market is very material ($1bn+). A NASDAQ listing is also possible over the coming months. Amryt is delivering on its strategy and we think the stock presents a compelling investment opportunity. Our price target is £3.20.
May 11 2020, 07:20 IST/BST